Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
biotech
boston blog main
clinical trials
boston top stories
san francisco blog main
national top stories
new york blog main
fda
san francisco top stories
cancer
ipo
new york top stories
san diego blog main
national
raleigh-durham blog main
raleigh-durham top stories
san diego top stories
texas blog main
texas top stories
boston
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
indiana blog main
indiana top stories
investing
seattle blog main
seattle top stories
wisconsin blog main
wisconsin top stories
medical device
cancer drugs
novartis
startups
venture capital
biogen
What
ipo
24
×
medicines
new
company
drug
million
public
therapeutics
bio
biotech
companies
life
science
week
cancer
developing
raised
roundup
ipos
research
way
biotechs
firms
genetic
plans
tests
activity
based
biogen
brings
covid
days
deal
diseases
dyne
experimental
fda
files
hasn’t
haul
Language
unset
Current search:
ipo
×
@xconomy.com
4 months ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
5 months ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
5 months ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
6 months ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
7 months ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
8 months ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
10 months ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
10 months ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
11 months ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
1 year ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
1 year ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
1 year ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
1 year ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
1 year ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com
1 year ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
1 year ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com
1 year ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
1 year ago
Acelity Sells to 3M in Deal Valued at $6.7 Billion, Ending IPO Plan
@xconomy.com
2 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
2 years ago
Synthorx Files for IPO to Advance Enhanced Cytokine Drugs
@xconomy.com
2 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
2 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@techcrunch.com
2 years ago
Public shareholders got high today on Tilray, the first marijuana company to IPO on Nasdaq
@xconomy.com
2 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M